<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003479</url>
  </required_header>
  <id_info>
    <org_study_id>2020L001-2A</org_study_id>
    <nct_id>NCT05003479</nct_id>
  </id_info>
  <brief_title>Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Kangtai Biological Products Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Minhai Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Kangtai Biological Products Co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of&#xD;
      the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the&#xD;
      experimental vaccine in healthy population aged 3 to 17 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse reactions/events</measure>
    <time_frame>0-28 days after each vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>within 12 months post full vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal indicators of laboratory safety examinations(including blood routine, blood biochemistry, urine routine, thyroid function and coagulation function)</measure>
    <time_frame>Day 3 after each dose of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days, 3 months, 6 months and 12 months post full vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of SARS-CoV-2 IgG binding antibody</measure>
    <time_frame>28 days, 3 months, 6 months and 12 months post full vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>28 days post full vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of SARS-CoV-2 IgG binding antibody</measure>
    <time_frame>28 days post full vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositive rate of SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>3 months, 6 months and 12 months post full vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositive rate of SARS-CoV-2 IgG binding antibody</measure>
    <time_frame>3 months, 6 months and 12 months post full vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>candidate vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 Vaccine (Vero Cells), Inactivated</intervention_name>
    <description>2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.</description>
    <arm_group_label>candidate vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy residents aged 3 to 17 years at the time of consent&#xD;
&#xD;
          -  Subjects and/or their guardian agree to sign the informed consent forms voluntarily.&#xD;
&#xD;
          -  Be able to comply with study requirements/procedures.&#xD;
&#xD;
          -  Axillary temperature ≤ 37.0℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Within 14 days before vaccination, subjects have been abroad and to&#xD;
             villages/communities experienced COVID-19 epidemics, and in contact with COVID-19&#xD;
             cases or suspected cases. Subjects are under isolation observation, or living in the&#xD;
             villages/communities with COVID-19 cases or suspected cases;&#xD;
&#xD;
          -  Confirmed cases, suspected cases or asymptomatic cases with COVID-19 (refer to&#xD;
             Information System of China Disease Prevention and Control);&#xD;
&#xD;
          -  Subjects with history of SARS virus infection by self-reported;&#xD;
&#xD;
          -  Positive in throat swab through RT-PCR;&#xD;
&#xD;
          -  History of vaccination of various COVID-19 vaccines or positive in SARS-CoV-2 antibody&#xD;
             test;&#xD;
&#xD;
          -  Positive urine pregnancy test for females with menarche&#xD;
&#xD;
          -  With abnormal indicators, such as blood biochemistry, blood routine, urine routine,&#xD;
             thyroid function and coagulation function which might show clinical meaning, before&#xD;
             administration;&#xD;
&#xD;
          -  History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin&#xD;
             eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known&#xD;
             composition of inactivated SARS-CoV-2 vaccine;&#xD;
&#xD;
          -  History or family history of convulsion, epilepsy, encephalopathy or mental illness;&#xD;
&#xD;
          -  Subjects with congenital malformations or developmental disorders, genetic defects,&#xD;
             severe malnutrition, etc.;&#xD;
&#xD;
          -  Subjects with known or suspected diseases include: severe respiratory diseases, severe&#xD;
             cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable&#xD;
             hypertension, diabetic complications, malignant tumors, various acute diseases or&#xD;
             acute onset of chronic diseases;&#xD;
&#xD;
          -  Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma,&#xD;
             leukemia or other autoimmune diseases;&#xD;
&#xD;
          -  History of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation&#xD;
             disease);&#xD;
&#xD;
          -  Subjects receiving anti-TB treatment;&#xD;
&#xD;
          -  Subjects receiving other research drugs within 6 months before vaccination;&#xD;
&#xD;
          -  Subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently&#xD;
             oral or infusion for more than 14 days);&#xD;
&#xD;
          -  Subjects receiving blood products within 3 months before administration;&#xD;
&#xD;
          -  Subjects vaccinated with live attenuated vaccine within 14 days before vaccination;&#xD;
&#xD;
          -  Subjects vaccinated with other vaccine within 7 days before vaccination;&#xD;
&#xD;
          -  The researchers shall judge the other conditions which might be not in compliance with&#xD;
             the requirements of this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guifan Li, M.S</last_name>
    <phone>+861059613591</phone>
    <email>liguifan@biominhai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Provincial Center for Diseases Control and Prevention</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Huang</last_name>
      <phone>+8673184305935</phone>
      <email>ymlc01@hncdc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

